Search

Search results

Berlin Cures starts Phase IIa trial in heart failure

Ascenion’s portfolio company Berlin Cures has initiated a Phase IIa clinical study with its lead compound BC 007. The two-armed, randomized, open-label trial will evaluate the candidate’s safety and biological efficacy in patients with chronic heart failure. Phase I data demonstrated excellent tolerability, with no clinically relevant side effects.

BC 007, a DNA aptamer, selectively binds and neutralizes autoantibodies against G-protein-coupled receptors that causally contribute to heart failure. If successful it would provide the first causative treatment for millions of patients. Heart failure is one of the leading causes of death in the western world, with a socioeconomic burden that is equivalent to that of cancer.

For further information:
See Berlin Cures’ press release